Ignite Creation Date:
2024-05-06 @ 2:56 PM
Last Modification Date:
2024-10-26 @ 1:40 PM
Study NCT ID:
NCT04473963
Status:
COMPLETED
Last Update Posted:
2023-11-30
First Post:
2020-03-16
Brief Title:
FLOW-AF A Study to Evaluate the Ablacon Electrographic FLOW EGF Technology
Sponsor:
Ablacon Inc
Organization:
Cortex
Study Overview
Official Title:
A Randomized Controlled Study to Evaluate the Reliability of the Ablacon Electrographic FLOW EGF Algorithm Technology Ablamap Software to Identify AF Sources and Guide Ablation Therapy in Patients With Persistent Atrial Fibrillation
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FLOW-AF
Brief Summary:
This study is to evaluate the Ablacon Electrographic Flow EGF algorithm technology Ablamap Software
Detailed Description:
The objective of this study is to evaluate the reliability of the Ablacon Electrographic Flow EGF algorithm technology Ablamap Software to identify atrial fibrillation sources and guide ablation therapy in patients with persistent atrial fibrillation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None